IRLAB Therapeutics AB (publ) (IRLAB_A) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to a quarter presentation with the research company E-Lab Therapeutics in view of the first quarter of 2026. E-Lab researches on Parkinson's disease and addresses both the disease as such and the different symptoms. Christina Torfgård, CEO, Nicholas Waters Senior Vice President, R&D, and Gustav Albert, CFO, will present results and activities, followed by a Q&A session with analysts and your investment questions. Let me greet the CEO, Christina Torfgård. Welcome. Thank you, Mattias. I would like to welcome you to today's broadcast. an anledning av Q1, kvartal 1 som vi nu har släppt idag. Jag tänker att vi går vidare till den första bilden. Kan vi ta vidare? Här har vi vår disclaimer. Vi är ju listade på Nasdaq huvudmarknaden. Vi går vidare, tack. Här har vi dagens agenda. Jag kommer att gå igenom some events that have happened during the period and after the end of the period. Then I will hand over to Gustav Albert who will present the financial situation and what has happened during the period. And it will of course be focused on the business emission that we just went out and communicated yesterday. So I hope you will find it interesting. Then we have R&D, as Nicholas Waters will present what has happened in the different projects. And finally, I will summarize and then we have Q&A. Then we can take the next picture, thank you. This period has been really good, we have had many events. We have brought some of them in this picture. First of all, we have for 757, our medical candidate that we develop for parties that have which we do in collaboration with MSR Yotsuka. There we have started the study and in February we took in and dose the first individual in this study, which meant that after that we have the right to non-stop payments of 3 million US dollars...